Personalized cell therapy for advanced lung cancer shows early promise but trial halted
NCT ID NCT06491225
First seen May 06, 2026 · Last updated May 06, 2026
Summary
This early-phase study tested a personalized treatment called GTE-001, made from a patient's own tumor-fighting immune cells. It aimed to see if these cells could shrink tumors in adults with advanced lung adenocarcinoma that had worsened after chemotherapy. Only 2 people enrolled before the study was stopped, so we have very limited information on safety or effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED LUNG ADENOCARCINOMA；ADULT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing GoBroad Hospital
Beijing, Beijing Municipality, 102200, China
Conditions
Explore the condition pages connected to this study.